Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Yao
Yang
Y
Department of Oncology, Shanghai Sixth People's Hospital of Shanghai Jiaotong University, Shanghai 200233, China. yangyao_6@hotmail.com
Sun
Yuan-jue
YJ
Zhao
Hui
H
Guo
Yue-wu
YW
Lin
Feng
F
Cai
Xun
X
Tang
Xiao-chun
XC
Tang
Li-na
LN
Zhang
Wei
W
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C028098:10-hydroxycamptothecin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin